文献速递消化道肿瘤与早癌消化内镜

基于血液生物标志物(液体活检)与粪便检测或结肠镜筛查结直肠癌的成本效果比较

Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
PubMed 文献 · Gastroenterology · 2024-03-26

研究采用已建立的马尔可夫模型,比较每3年一次满足CMS最低阈值的血液检测与多靶点粪便DNA、年度FIT或每10年结肠镜筛查的效果。CMSmin较不筛查降低CRC发病率40%、死亡率52%,但效果低于其他方案;在相同成本下CMSmin每获得质量调整生命年需28500美元,而FIT、结肠镜和多靶点粪便DNA成本更低且更有效。

要点

  • CMSmin血液检测较不筛查降低CRC发病率40%、死亡率52%。
  • 多靶点粪便DNA、年度FIT或每10年结肠镜降低CRC发病率68%-79%、死亡率73%-81%。
  • CMSmin需达到FIT参与率的1.4至1.8倍才能匹配FIT的临床结局。

核心结论

  • CMSmin血液检测可为不采用已有方法的人群提供筛查,从而贡献于CRC控制。
  • 以血液检测替代已有有效CRC筛查方法,需更高的CRC和APL敏感性以产生与FIT相当的规划获益。
  • 高APL敏感性应作为筛查检测开发者的首要优先事项。

研究设计与样本

  • 使用已建立的马尔可夫模型进行模拟分析。
  • 比较每3年一次满足CMS最低阈值的血液检测与已建立的替代筛查方案。

主要发现

  • CMSmin较不筛查降低CRC发病率40%、死亡率52%。
  • 多靶点粪便DNA每3年、年度FIT或每10年结肠镜分别降低CRC发病率68%-79%、死亡率73%-81%。
  • 假设与多靶点粪便DNA成本相同,CMSmin较不筛查每获得质量调整生命年需28500美元;FIT、结肠镜和多靶点粪便DNA成本更低且更有效。
  • CMSmin若达到FIT参与率的1.4至1.8倍,可匹配FIT的临床结局。
  • APL敏感性是检测效果的关键决定因素。

关键数值与推荐

  • CMSmin定义:CRC敏感性74%、特异性90%。
  • 范式改变的血液检测:CRC敏感性>90%、APL敏感性80%、特异性90%、成本≤120-140美元,在参与率相当时较FIT具有成本效果。

临床怎么用

  • CMSmin可用于不采用已有筛查方法的人群。
  • 以血液检测替代已有有效CRC筛查方法需更高CRC和APL敏感性以匹配FIT的规划获益。
  • 高APL敏感性应作为筛查检测开发的首要优先事项。
  • APL检测不应因仅关注CRC的特异性定义而受罚。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Colorectal cancer (CRC) screening is highly effective but underused. Blood-based biomarkers (liquid biopsy) could improve screening participation. METHODS: Using our established Markov model, screening every 3 years with a blood-based test that meets minimum Centers for Medicare & Medicaid Services' thresholds (CMSmin) (CRC sensitivity 74%, specificity 90%) was compared with established alternatives. Test attributes were varied in sensitivity analyses. RESULTS: CMSmin reduced CRC incidence by 40% and CRC mortality by 52% vs no screening. These reductions were less profound than the 68%-79% and 73%-81%, respectively, achieved with multi-target stool DNA (Cologuard; Exact Sciences) every 3 years, annual fecal immunochemical testing (FIT), or colonoscopy every 10 years. Assuming the same cost as multi-target stool DNA, CMSmin cost $28,500/quality-adjusted life-year gained vs no screening, but FIT, colonoscopy, and multi-target stool DNA were less costly and more effective. CMSmin would match FIT's clinical outcomes if it achieved 1.4- to 1.8-fold FIT's participation rate. Advanced precancerous lesion (APL) sensitivity was a key determinant of a test's effectiveness. A paradigm-changing blood-based test (sensitivity >90% for CRC and 80% for APL; 90% specificity; cost ≤$120-$140) would be cost-effective vs FIT at comparable participation. CONCLUSIONS: CMSmin could contribute to CRC control by achieving screening in those who will not use established methods. Substituting blood-based testing for established effective CRC screening methods will require higher CRC and APL sensitivities that deliver programmatic benefits matching those of FIT. High APL sensitivity, which can result in CRC prevention, should be a top priority for screening test developers. APL detection should not be penalized by a definition of test specificity that focuses on CRC only.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ladabaum U, Mannalithara A, Weng Y, et al. Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy. Gastroenterology. 2024. PMID: 38552670. doi:10.1053/j.gastro.2024.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。